Snoop, spray 90 mcg/dose 15 ml

Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with alpha-adrenomimetic activity, causes narrowing of blood vessels of nasal mucosa, eliminating edema and hyperemia of nasal mucosa, restores nasal passageway, facilitates nasal breathing.

The action of the drug starts 5-10 minutes after its application and lasts up to 12 hours.

Indications

Active ingredient

Composition

1 ml of nasal spray contains:

The active ingredient:

Xylometazoline hydrochloride 0.5 mg or 1.0 mg

Associates:

Sea water – 250.0 mg,

Potassium dihydrophosphate – 0.45 mg,

Purified water – 754.35 mg or 753.85 mg.

Theoretical total weight is 1,005.3 mg.

How to take, the dosage

Intranasally.

Snoop® nasal spray 0.05%

In children aged 2 to 6 years, 1 injection in each nostril (can be repeated if necessary), up to three times a day.

Adults and children over 6 years of age: 2 injections in each nostril, up to three times a day.

Snoop® nasal spray 0.1%

Adults and children over 6 years of age: 1 injection in each nostril (can be repeated if necessary), up to three times a day.

Snoop® Nasal Spray 0.1% should not be used in children under 6 years of age.

The drug should not be used more than 3 times a day, the course of treatment should not exceed 7 days.

The nasal passages should be cleaned before use.

Pick off the protective cap. Before first use, squeeze the rim of the spray nozzle several times until an even cloud of “mist” appears. The bottle is ready to use again.

In application, insert the nozzle into the nasal cavity and press once on the rim. Hold the bottle vertically. Do not spray horizontally or downward.

Injection immediately afterwards is recommended with a light nose job. After use, cover the vial with the protective cap.

Each vial must be used individually.

After therapy, the drug can only be reapplied after a few days.

The duration of use in children should be consulted with the physician. In cases of chronic rhinitis, Snup® 0.05% and 0.1% should only be used under medical supervision, because of the risk of nasal mucosal atrophy.

If there is no improvement after treatment, or if symptoms worsen, or new symptoms develop, a physician should be consulted.

To use the drug only according to the indication, route of administration, and dosage listed in the directions.

Interaction

The concomitant use of xylometazoline with monoamine oxidase inhibitors (MAOIs), tricyclic and tetracyclic antidepressants, other local vasoconstrictors (decongestants),

as well as other drugs that increase blood pressure may lead to increased blood pressure, so the simultaneous use of these medicines is contraindicated.

If you are using the above or other medicines (including over-the-counter medicines), consult your doctor before using Snoop®.

Special Instructions

The seawater contained in the product helps maintain the normal physiological condition of the nasal mucosa due to its ability to improve the function of the atomizing epithelium and normalize mucus production in the mucosal bocalytic cells.

Do not use continuously for more than 7 days.

The recommended doses should not be exceeded, especially in children and the elderly.

Long-term (more than 7 days) use or overdose of xylomethasoline may decrease the therapeutic effect of the drug and also increases the risk of reactive hyperemia and nasal mucosal atrophy.

Synopsis

Features

Contraindications

Side effects

Classification of the frequency of adverse reactions: very common (> 1/10); common (> 1/100 to < 1/10); infrequent (> 1/1000 to < 1/100); rare (> 1/10 000 to < 1/1000); very rare (< 1/10000).

Immune system disorders:

Very rare: hypersensitivity reactions (angioedema, rash, itching).

Nervous system disorders:

Often: headache.

Rarely: insomnia, depression (with prolonged use in high doses).

very rarely: anxiety, fatigue, paresthesias, hallucinations and seizures (mostly in children).

Senses:

Very rare: impairment of visual clarity.

Cardiovascular system disorders:

Rarely: sensation of palpitations, increased blood pressure.

Very rare: tachycardia, arrhythmia.

Respiratory system disorders:

Often: irritation and/or dryness of nasal mucosa, burning, tingling, sneezing, hypersecretion of nasopharyngeal mucosa.

Rarely: after using the drug there may be increased nasal mucosal edema (reactive hyperemia), nasal bleeding.

Digestive system disorders:

Often: nausea.

Rarely: vomiting.

Local reactions:

Often: burning at the site of application.

If you experience or worsen the side effects listed in the instructions, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

Symptoms:

In an overdose of the drug, the clinical picture is an alternation of phases of central nervous system arousal (restlessness, agitation, hallucinations, seizures) with phases of central nervous system depression (decreased body temperature, lethargy, drowsiness, coma).

The following symptoms may also occur: miosis, mydriasis, increased sweating, increased body temperature, pallor, cyanosis, nausea and vomiting, tachycardia, bradycardia, cardiac arrhythmias, cardiac arrest,

heart palpitations, increased blood pressure, reduced blood pressure to shock, pulmonary edema, depressed breathing and apnea, psychogenic disorders.

In children in overdose, there are dominant central effects with seizures, coma and bradycardia, apnea, and increased blood pressure followed by hypotension.

Treatment:

Symptomatic, under medical supervision.

In case of accidental ingestion of the drug – administration of activated charcoal, gastric lavage.

In severe overdose, intensive hospital therapy is indicated.

In serious cases non-selective alpha-adrenoblockers may be used to reduce blood pressure, antipyretic drugs, intubation and artificial ventilation.

Pregnancy use

Contraindicated in pregnancy, with caution breast-feeding.

Similarities